Immuno-OncologyVeröffentlicht am: 31. März 2019
AACR 2019: Patients with high-grade neuroendocrine carcinoma benefit from immune checkpoint inhibitor combination
Results from a phase II clinical trial presented at the AACR Annual Meeting 2019 demonstrate that the combination of nivolumab and ipilimumab could be efficacious in high-grade neuroendocrine carcinoma.
